# ImmunoACT

> ImmunoACT delivers India’s leading CAR\-T cell therapy for blood cancer treatment, lymphoma treatment, and leukemia care\. Learn how indigenous CAR\-T advances affordable cancer treatment nationwide\.

Generated by Yoast SEO v28.0, this is an llms.txt file, meant for consumption by LLMs.

## Pages
- [About](https://immunoact.com/about-us/)
- [Contact us](https://immunoact.com/contact/)
- [Privacy Policy](https://immunoact.com/privacy-policy/)
- [Our Authorized Treatment Centers](https://immunoact.com/hospital_list/)
- [NexCAR19\-HCP](https://immunoact.com/nexcar19-hcp/)
- [NexCAR19\-Patients](https://immunoact.com/nexcar19/)
- [Home](https://immunoact.com/)
- [Publications](https://immunoact.com/publications/)
- [Science](https://immunoact.com/science/)
- [Media](https://immunoact.com/news-media/)
- [Press Release](https://immunoact.com/press-release/)
- [Partnered Hospitals](https://immunoact.com/partnered-hospitals/)

## Press
- [Beyond Borders: ImmunoACT and India's Emergence as one of the World's Most Accessible CAR\-T Destination](https://immunoact.com/?press=beyond-borders-immunoact-and-indias-emergence-as-one-of-the-worlds-most-accessible-car-t-destination)
- [Two years since launch, India’s first indigenous CAR\-T therapy enters its scale phase](https://immunoact.com/?press=two-years-since-launch-indias-first-indigenous-car-t-therapy-enters-its-scale-phase)
- [Renewed hope: An Indore MPPSC aspirant’s recovery after relapsed leukemia](https://immunoact.com/?press=renewed-hope-an-indore-mppsc-aspirants-recovery-after-relapsed-leukemia)
- [From Mauritius to Mumbai: How a Made in India CAR\-T therapy gave one man his life back](https://immunoact.com/?press=from-mauritius-to-mumbai-how-a-made-in-india-car-t-therapy-gave-one-man-his-life-back)
- [Back on Roads: How an Indian\- Made cancer Therapy Helped a Young Cyclist Restart His Life](https://immunoact.com/?press=back-on-roads-how-an-indian-made-cancer-therapy-helped-a-young-cyclist-restart-his-life)

## Press Release
- [ImmunoACT Celebrates Milestone as Prime Minister Unveils NexCAR19 at ESTIC 2025, India's First Indigenous CAR\-T Therapy](https://immunoact.com/press-release/pm-modi-unveils-nexcar19-at-estic/)
- [ImmunoACT Partners with Mango Sciences to Launch World’s First Bridge Financing and Value\-Based Plan for CAR\-T Therapy, Enhancing Access for Cancer Patients in India](https://immunoact.com/press-release/immunoact-partners-with-mango-sciences-to-launch-worlds-first-bridge-financing-and-value-based-plan-for-car-t-therapy-enhancing-access-for-cancer-patients-in-india/)
- [ImmunoACT partners with Cipla to launch NexCAR19 \(Talicabtagene autoleucel\) for Blood Cancers in Africa](https://immunoact.com/press-release/immunoact-partners-with-cipla/)

## Publications
- [Talicabtagene Autoleucel for Relapsed or Refractory B\-cell Malignancies: Results from an Open\-label, Multicentre, Phase 1/2 Study](https://immunoact.com/publication/talicabtagene-autoleucel-for-relapsed-or-refractory-b-cell-malignancies-results-from-an-open-label-multicentre-phase-1-2-study-2/)
- [Tali\-cel is a safe and effective therapy in patients with Relapsed/Refractory Bcell non\-Hodgkin lymphoma that allows equitable access\- a real\-world experience from India\.](https://immunoact.com/publication/tali-cel-is-a-safe-and-effective-therapy-in-patients-with-relapsed-refractory-bcell-non-hodgkin-lymphoma-that-allows-equitable-access-a-real-world-experience-from-india/)
- [A multicentre Phase I clinical trial demonstrates manufacturing feasibility, safety and activity of novel humanized BCMA\-directed CAR\-T cell therapy\.](https://immunoact.com/publication/a-multicentre-phase-i-clinical-trial-demonstrates-manufacturing-feasibility-safety-and-activity-of-novel-humanized-bcma-directed-car-t-cell-therapy-2/)
- [A multicentre Phase I clinical trial demonstrates manufacturing feasibility, safety and activity of novel humanized BCMA\-directed CAR\-T cell therapy\.](https://immunoact.com/publication/a-multicentre-phase-i-clinical-trial-demonstrates-manufacturing-feasibility-safety-and-activity-of-novel-humanized-bcma-directed-car-t-cell-therapy/)
- [Tali\-cel is a safe and effective therapy in patients with Relapsed/Refractory B\-cell non\-Hodgkin lymphoma that allows equitable access\- a real\-world experience from India](https://immunoact.com/publication/tali-cel-is-a-safe-and-effective-therapy-in-patients-with-relapsed-refractory-b-cell-non-hodgkin-lymphoma-that-allows-equitable-access-a-real-world-experience-from-india/)

## Stores
- [NAMCO Hospital, Nashik](https://immunoact.com/store-locator/namco-hospital-nashik/)
- [Yenepoya University Medical College Hospital, Mangalore](https://immunoact.com/store-locator/yenepoya-university-medical-college-hospital-mangalore/)
- [Safdarjung Hospital, New Delhi](https://immunoact.com/store-locator/safdarjung-hospital-new-delhi/)
- [Vishesh Jupiter Hospital, Indore](https://immunoact.com/store-locator/vishesh-jupiter-hospital-indore/)
- [NCI, Nagpur](https://immunoact.com/store-locator/nci-nagpur/)

## Optional
- [Sitemap index](https://immunoact.com/sitemap_index.xml)